These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 25213670

  • 1. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y, Hong Y, Xu Y, Liu P, Guo DH, Chen Y.
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [Abstract] [Full Text] [Related]

  • 2. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B, Ding CM, Li YX, Peng JC, Geng N, Qin WW.
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [Abstract] [Full Text] [Related]

  • 3. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
    Zhu F, Dai C, Fu Y, Loo JF, Xia D, Gao SP, Ma Z, Chen Z.
    Oncotarget; 2016 Feb 23; 7(8):9462-76. PubMed ID: 26843613
    [Abstract] [Full Text] [Related]

  • 4. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
    Danni X, Jiangzheng Z, Huamao S, Yinglian P, Changcheng Y, Yanda L.
    Bioengineered; 2021 Dec 23; 12(1):7335-7347. PubMed ID: 34612768
    [Abstract] [Full Text] [Related]

  • 5. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
    Yeh CT, Huang WC, Rao YK, Ye M, Lee WH, Wang LS, Tzeng DT, Wu CH, Shieh YS, Huang CY, Chen YJ, Hsiao M, Wu AT, Yang Z, Tzeng YM.
    Carcinogenesis; 2013 Dec 23; 34(12):2918-28. PubMed ID: 23880305
    [Abstract] [Full Text] [Related]

  • 6. PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway.
    Zhang W, Wang Y, Tang Q, Li Z, Sun J, Zhao Z, Jiao D.
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Sep 23; 397(9):6889-6901. PubMed ID: 38573552
    [Abstract] [Full Text] [Related]

  • 7. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.
    Am J Respir Cell Mol Biol; 2013 Aug 23; 49(2):241-50. PubMed ID: 23526220
    [Abstract] [Full Text] [Related]

  • 8. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
    Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, Huang L.
    Sci Rep; 2015 Jul 13; 5():8477. PubMed ID: 26166037
    [Abstract] [Full Text] [Related]

  • 9. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, Ismail K, Kratzke RA.
    Cancer Gene Ther; 2019 Nov 13; 26(11-12):411-418. PubMed ID: 30622322
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.
    Zhang W, Qiao B, Fan J.
    Pharmazie; 2018 Jul 01; 73(7):386-392. PubMed ID: 30001772
    [Abstract] [Full Text] [Related]

  • 11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J, Meng Q, Zhao Y, Chen X, Cai L.
    BMC Cancer; 2016 Jul 13; 16():470. PubMed ID: 27411790
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
    Yang X, Gao Y, Liu Q, Wan L, Liu H, Bian W, Du Y, Huang C.
    Oncol Rep; 2021 Feb 13; 45(2):459-468. PubMed ID: 33416163
    [Abstract] [Full Text] [Related]

  • 13. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM, Ge F, Chen XJ, Tang C, Ma J.
    Eur Rev Med Pharmacol Sci; 2019 Jun 13; 23(12):5242-5250. PubMed ID: 31298375
    [Abstract] [Full Text] [Related]

  • 14. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q.
    Thorac Cancer; 2021 Oct 13; 12(19):2551-2563. PubMed ID: 34469060
    [Abstract] [Full Text] [Related]

  • 15. CDKN2A inhibited ferroptosis through activating JAK2/STAT3 pathway to modulate cisplatin resistance in cervical squamous cell carcinoma.
    Yong X, Zhang Y, Tang H, Hu H, Song R, Wu Q.
    Anticancer Drugs; 2024 Sep 01; 35(8):698-708. PubMed ID: 38748610
    [Abstract] [Full Text] [Related]

  • 16. Induction of autophagy by an oleanolic acid derivative, SZC017, promotes ROS-dependent apoptosis through Akt and JAK2/STAT3 signaling pathway in human lung cancer cells.
    Song Y, Kong L, Sun B, Gao L, Chu P, Ahsan A, Qaed E, Lin Y, Peng J, Ma X, Zhang J, Wang S, Tang Z.
    Cell Biol Int; 2017 Dec 01; 41(12):1367-1378. PubMed ID: 28880428
    [Abstract] [Full Text] [Related]

  • 17. C-X-C chemokine receptor 2 correlates with unfavorable prognosis and facilitates malignant cell activities via activating JAK2/STAT3 pathway in non-small cell lung cancer.
    Wei L, Liu Y, Ma Y, Ding C, Zhang H, Lu Z, Gu Z, Zhu C.
    Cell Cycle; 2019 Dec 01; 18(24):3456-3471. PubMed ID: 31731888
    [Abstract] [Full Text] [Related]

  • 18. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
    Chen RL, Wang Z, Huang P, Sun CH, Yu WY, Zhang HH, Yu CH, He JQ.
    Int Immunopharmacol; 2021 May 01; 94():107357. PubMed ID: 33715980
    [Abstract] [Full Text] [Related]

  • 19. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y, Xu T, Zhong S, Wang B, Zhang H, Wang X, Wang P, Li G, Yang S.
    Life Sci; 2019 Dec 15; 239():116984. PubMed ID: 31647948
    [Abstract] [Full Text] [Related]

  • 20. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ, Yang ZX, Dai XT, Chen YF, Yang HP, Zhou XD.
    Apoptosis; 2017 Sep 15; 22(9):1157-1168. PubMed ID: 28677094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.